Funding for insurance businesses and insurtechs in South Africa

Which insurance business are you — and which capital do you actually need?

The sector’s three models raise completely differently, and conflating them loses any funder who knows the industry. A licensed insurer raising regulatory capital operates under the Prudential Authority’s SAM (Solvency Assessment and Management) regime — that capital is permanent, tightly structured, and priced for solvency, not growth. A UMA (underwriting management agency) writes on a carrier’s licence, holds no regulatory capital of its own, and raises growth capital against underwriting results and book persistency — with the durability of the carrier relationship as the central diligence question. An insurtech distributing or administering is a technology raise judged on insurance metrics: cost per policy acquired, persistency, and the loss ratio of the book it builds.

The numbers that decide insurance diligence

Persistency and loss ratios above everything — growth that lapses is expense wearing revenue’s clothes, and funders in this sector model lapse behaviour before they model growth. For UMAs and cell-captive businesses: binder terms, profit-share mechanics, and what happens to the book if the carrier relationship ends. For insurtechs: whether distribution economics survive without founder-led selling, and the gap between policies sold and policies still active at month twelve. Claims-handling capability is examined, not assumed — an underwriting business that cannot evidence its claims discipline is pricing risk it cannot manage.

Who funds South African insurance businesses

Specialist financial-services private equity for UMAs and established books; the corporate venture arms of the large insurers — strategic capital that often prefigures the exit; international fintech and insurtech investors entering through the corridor; and, for licensed carriers, institutional capital structured for SAM compliance. The strategic route matters: trade sale to a carrier is the sector’s dominant exit, which makes corporate venture money both capital and optionality — and makes a run sale process the honest comparison for any established UMA weighing a raise.

Structures that work — and the one error to avoid

Growth equity against persistency-evidenced books; mezzanine for distribution expansion where dilution is unjustified; earn-out-heavy trade sales tied to book retention. The error: pitching regulatory capital needs as a growth story, or vice versa. Funders price the two entirely differently, and a deck that blurs them signals the founder doesn’t know which business they’re in. Start with the readiness check.

What kills insurance raises

Lapse rates discovered rather than disclosed; carrier concentration presented as partnership; loss ratios modelled from incomplete claims data; distribution economics that only work with the founder selling; and — for insurtechs — growth metrics that count policies sold rather than policies alive. Disclosure with a remediation plan survives diligence; discovery does not.

The questions insurance funders will ask

• What is persistency at month 12 and month 24, by cohort and by channel?
• What is the loss ratio of the book you have built — and how complete is the claims data behind it?
• For UMAs: what are the binder terms, the profit-share mechanics, and the notice period on the carrier relationship?
• What happens to the book if that carrier exits?
• What is customer acquisition cost by channel, and which channels survive without founder involvement?
• How is claims handling resourced, and what does complaint history show?
• Which regulatory perimeter are you in — and has the FSCA or PA ever queried it?

These are answerable in an afternoon by a business that tracks them — and unanswerable in a quarter by one that doesn’t. The difference is the raise.

Cell captives and the licence-light routes

South Africa’s cell-captive structures — renting a licensed insurer’s balance sheet through a dedicated cell — let a distribution business underwrite economically without holding a licence, converting commission income into underwriting profit participation. Funders treat a well-run cell as a value multiplier: it evidences underwriting discipline and captures margin, while keeping regulatory capital off the raise. The diligence questions shift accordingly — cell solvency, the promoter agreement’s terms, and what happens at termination. For distribution businesses with persistency-proven books, moving from pure commission to cell participation before a raise routinely changes the multiple more than a year’s growth would.

One further exhibit worth preparing: the FSCA conduct file. Complaint ratios, TCF (treating customers fairly) evidence and claims-turnaround data are increasingly requested in insurance diligence — partly as regulatory hygiene, partly because conduct quality predicts persistency. A clean, documented conduct position is cheap to maintain and expensive to reconstruct mid-process.

Last, diversify the carrier bench before the raise, not during it: a UMA with two binder relationships — even with one dormant — answers the concentration question structurally, and the negotiating position with the primary carrier improves the day the alternative exists.